A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-γ versus placebo in the treatment of rheumatoid arthritis

Arthritis and Rheumatism

Volumn 40, Issue 1, 1997, Pages 62-68

  Veys, Eric M ^c   Menkes, Charles Joël ^a   Emery, Paul ^b  

^a Institut Cochin   (France)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PREDNISONE; RECOMBINANT GAMMA INTERFERON;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE STRENGTH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RIGIDITY; SKIN ALLERGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031030787     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400110     Document Type: Article

References (24)

1. Trinchieri G, Perussia B: Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 6:131-136, 1985
2. Lengyel P: Biochemistry of interferons and their actions. Annu Rev Biochem 51:251-282, 1982
3. Cowing C, Frohman MA: Interferon, class II histocompatibility antigens and autoimmunity. In, Biologically Based Immunomodulators in the Therapy of Rheumatic Disease. Edited by SH Pincus, DS Pisetsky, LJ Rosenwasser. New York, Elsevier, 1986
4. Zilly A, Obert HJ: Therapie der chronischen Polyarthritis. Ergebnisse einer Pilot-Studie mit Lymphokines. München Medizinische Wochenschrift 128:87-89, 1986
5. Lemmel EM, Brackertz D, Franke M, Gaus W, Hartl PW, Machalke U, Mielke H, Obert H-J, Peter HH, Sieper J, Sprekeler R, Stierle H: Results of multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 8:87-93, 1988
6. Lemmel EM, Gaus W, Hofschneider PH: Multicenter double-blind trial of interferon-γ versus placebo in the treatment of rheumatoid arthritis (letter). Arthritis Rheum 34:1621-1622, 1991
7. Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, Schindler JD: Double-blind trial of recombinant γ-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 32:964-973, 1989
8. Machold KP, Neumann K, Smolen JS: Recombinant human interferon γ in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann Rheum Dis 51:1039-1043, 1992
9. Veys EM, Mielants H, Verbruggen G, Grosclaude JP, Meyer W, Galazka A, Schindler J: Interferon gamma in rheumatoid arthritis - a double blind study comparing human recombinant interferon gamma with placebo. J Rheumatol 15:570-574, 1988
10. Wolfe F, Cathey MA, Hawley DJ, Baiser JP, Schindler JD: Clinical trial with r-IFN-gamma in rheumatoid arthritis. In, Biologically Based Immunomodulators in the Therapy of Rheumatoid Diseases. Edited by SH Pincus, DS Pisetsky, LJ Rosenwasser. New York, Elsevier, 1986
11. Seitz M, Manz G, Franke M: Use of recombinant human interferon gamma in patients with rheumatoid arthritis. Z Rheumatol 45:93-99, 1986
12. Lemmel EM, Franke M, Gaus W, Lemmel EM, Franke M, Gaus W, Hartl PW, Hofschneider PH, Miehlke K, Machalke U, Obert H-J: Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 7:127-132, 1987
13. Firestein GS, Weisman MH, Zvaifler NJ: Parenteral IFN-γ in rheumatoid arthritis: effect on disease activity and peripheral blood monocytes (abstract). Arthritis Rheum 30 (suppl 4):S115, 1987
14. Cannon GW, Emkey RD, Denes A, Cohen SA, Saway PA, Wolfe F, Jaffer AM, Weaver AL, Cogen L, Gulinello J, Kennedy SA, Schindler JD: Prospective two year follow-up of recombinant interferon-gamma in rheumatoid arthritis. J Rheumatol 17:304-310, 1990
15. Sprekeler R, Lemmel EM, Obert HJ: Correlation of clinical and serological findings in patients with rheumatoid arthritis treated for one year with interferon-gamma. Z Rheumatol 49:1-17, 1990
16. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-665, 1949
17. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1995
18. Neter J, Washerman W, Kutner M: Applied Linear Statistical Models. Homewood, IL, Richard D. Irwin Inc., 1985
19. SAS Institute, Inc.: SAS User's Guide: Statistics. Version 6. Third edition. Cary, NC, SAS Institute, Inc, 1988
20. Armitage P, Berry G: Statistical Methods in Medical Research. Second edition. Oxford, Blackwell Scientific Publications, 1987
21. Ghezzi P, Dinnarello PA: Interleukin-1. III. Specific inhibition of interleukin-I production by gamma-interferon. J Immunol 140: 4238-4242, 1988
22. 2 and collagenase release. Ann Rheum Dis 49:512-516, 1990
23. Cannon GW, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, Fay AM: Prospective five year followup of recombinant interferon-gamma in rheumatoid arthritis (abstract). Arthritis Rheum 34 (suppl 9):S91, 1991
24. Pincus SH, Cannon GW, Ward RJ: In vivo administration of interferon-gamma to patients with rheumatoid arthritis decreases number of circulating B cells. J Rheumatol 17:751-757, 1990